You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for dasabuvir sodium; ombitasvir; paritaprevir; ritonavir and what is the scope of patent protection?

Dasabuvir sodium; ombitasvir; paritaprevir; ritonavir is the generic ingredient in one branded drug marketed by Abbvie and is included in one NDA. There are twenty patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Dasabuvir sodium; ombitasvir; paritaprevir; ritonavir has six hundred and three patent family members in fifty-four countries.

Summary for DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR
Generic Entry Dates for DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET, EXTENDED RELEASE;ORAL
Generic Entry Dates for DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET, TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Abbvie VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Abbvie VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Abbvie VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Abbvie VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Abbvie VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Abbvie VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 ⤷  Try a Trial ⤷  Try a Trial
Abbvie VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

Country Patent Number Title Estimated Expiration
Eurasian Patent Organization 024100 МЕТИЛ {(2S,3R)-1-[(2S)-2-{5-[(2R,5R)-1-{3,5-ДИФТОР-4-[4-(4-ФТОРФЕНИЛ)ПИПЕРИДИН-1-ИЛ]ФЕНИЛ}-5-(6-ФТОР-2-{(2S)-1-[N-(МЕТОКСИКАРБОНИЛ)-О-МЕТИЛ-L-ТРЕОНИЛ]ПИРРОЛИДИН-2-ИЛ}-1H-БЕНЗИМИДАЗОЛ-5-ИЛ)ПИРРОЛИДИН-2-ИЛ]-6-ФТОР-1H-БЕНЗИМИДАЗОЛ-2-ИЛ}ПИРРОЛИДИН-2-ИЛ]-3-МЕТОКСИ-1-ОКСОБУТАН-2-ИЛ}КАРБАМАТ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ВКЛЮЧАЮЩАЯ ЕГО, И СПОСОБ ЛЕЧЕНИЯ ИНФЕКЦИИ ГЕПАТИТА C (METHYL {(2S,3R)-1-[(2S)-2-{5-[(2R,5R)-1-{3,5-DIFLUORO-4-[4-(4-FLUOROPHENYL)PIPERIDIN-1-YL]PHENYL}-5-(6-FLUORO-2-{(2S)-1-[N-(METHOXYCARBONYL)-O-METHYL-L-THREONYL]PYRROLIDIN-2-yl}-1H-BENZIMIDAZOL-5-YL)PYRROLIDIN-2-YL]-6-FLUORO-1H-BENZIMIDAZOL-2-YL}PYRROLIDIN-1-YL]-3-METHOXY-1-OXOBUTAN-2-YL}CARBAMATE, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND METHOD OF TREATING HCV INFECTION) ⤷  Try a Trial
Argentina 088463 METODOS PARA EL TRATAMIENTO DE HCV ⤷  Try a Trial
Hungary S1500020 ⤷  Try a Trial
China 104628655 ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF ⤷  Try a Trial
Hungary S1500013 ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 2010030359 ⤷  Try a Trial
Argentina 086181 METODO PARA PREPARAR INHIBIDORES MACROCICLICOS INHIBIDORES DE SERINA PROTEASAS DEL VIRUS DE LA HEPATITIS C ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2203431 92666 Luxembourg ⤷  Try a Trial PRODUCT NAME: DASABUVIR OU UN SEL QUI EN DERIVE, Y COMPRIS DASABUVIR SODIUMMONOHYDRATE. FIRST REGISTRATION: 20150119
2203431 C02203431/01 Switzerland ⤷  Try a Trial FORMER OWNER: ABBVIE BAHAMAS LIMITED, BS
2368890 92668 Luxembourg ⤷  Try a Trial PRODUCT NAME: OMBITASVIR, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE (VIEKIRAX R); FIRST REGISTRATION DATE: 20150119
2340029 PA2015011,C2340029 Lithuania ⤷  Try a Trial PRODUCT NAME: PARITAPREVIRAS; REGISTRATION NO/DATE: EU/1/14.982 20150115
2368890 C20150016 00154 Estonia ⤷  Try a Trial PRODUCT NAME: OMBITASVIIR;REG NO/DATE: EU/1/14/982 19.01.2015
2368890 33/2015 Austria ⤷  Try a Trial PRODUCT NAME: OMBITASVIR, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/982 (MITTEILUNG) 20150119
2692346 300901 Netherlands ⤷  Try a Trial PRODUCT NAME: PIBRENTASVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/17/1213 20170728
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.